|Trade names||Prevacid, others|
|Drug class||Proton pump inhibitor|
|Main uses||Peptic ulcer disease, gastroesophageal reflux disease, Zollinger–Ellison syndrome|
|Side effects||Constipation, abdominal pain, nausea|
|By mouth, IV|
|Defined daily dose||30 mg|
|Bioavailability||80% or more|
|Metabolism||Liver (CYP3A4- and CYP2C19-mediated)|
|Elimination half-life||1.0–1.5 hours|
|Excretion||Kidney and fecal|
|Chemical and physical data|
|Molar mass||369.363 g·mol−1|
|3D model (JSmol)|
Lansoprazole, sold under the brand name Prevacid among others, is a medication which reduces stomach acid. It is used to treat peptic ulcer disease, gastroesophageal reflux disease, and Zollinger–Ellison syndrome. Effectiveness is similar to other proton pump inhibitors (PPIs). It is taken by mouth. Onset is over a few hours and effects last up to a couple of days.
Common side effects include constipation, abdominal pain, and nausea. Serious side effects may include osteoporosis, low blood magnesium, Clostridium difficile infection, and pneumonia. Use in pregnancy and breastfeeding is of unclear safety. It works by blocking H+/K+-ATPase in the parietal cells of the stomach.
Lansoprazole was patented in 1984 and came into medical use in 1992. It is available as a generic medication. A one-month supply, in the United Kingdom, costs the NHS less than £5, as of 2019[update]. In the United States, the wholesale cost of this amount is about $5.40, as of 2019. In 2017, it was the 188th most commonly prescribed medication in the United States, with more than three million prescriptions.
Lansoprazole is used for treatment of:
- Ulcers of the stomach and duodenum, and NSAID-induced ulcers
- Helicobacter pylori infection, alongside antibiotics (adjunctive treatment), treatment to kill H. pylori causing ulcers or other problems involves using two other drugs besides lansoprazole known as "triple therapy", and involves taking twice daily for 10 or 14 days lansoprazole, amoxicillin, and clarithromycin
- Gastroesophageal reflux disease
- Zollinger-Ellison syndrome
There is no evidence that it works better than other PPIs.
The defined daily dose is 30 mg by mouth.
Side effects of PPIs in general and lansoprazole in particular may include:
- Common: diarrhea, abdominal pain
- Infrequent: dry mouth, insomnia, drowsiness, blurred vision, rash, pruritus
- Rarely and very rarely: taste disturbance, liver dysfunction, peripheral oedema, hypersensitivity reactions (including bronchospasm, urinary, angioedema, anaphylaxis), photosensitivity, fever, sweating, depression, interstitial nephritis, blood disorders (including leukopenia, leukocytosis, pancytopenia, thrombocytopenia), arthralgia, myalgia, skin reactions including (erythroderma Stevens–Johnson syndrome, toxic epidermal necrolysis, bullous eruption)
PPIs may be associated with a greater risk of hip fractures and Clostridium difficile-associated diarrhea.: 22
Lansoprazole interacts with several other drugs, either due to its own nature or as a PPI.
- PPIs reduce absorption of antifungals (itraconazole and ketoconazole)  and possibly increase digoxin in plasma
- Increases plasma concentrations of cilostazol (risk of toxicity)
Lansoprazole possibly interacts with, among other drugs:
- iron salts
- aminophylline and theophylline
It is a racemic 1:1 mixture of the enantiomers dexlansoprazole and levolansoprazole. Dexlansoprazole is an enantiomerically pure active ingredient of a commercial drug as a result of the enantiomeric shift. Lansoprazole's plasma elimination half-life (1.5 h) is not proportional to the duration of the drug's effects to the person (i.e. gastric acid suppression).
Lansoprazole was originally synthesized at Takeda and was given the development name AG 1749. Takeda patented it in 1984 and the drug launched in 1991. In the United States, it was approved for medical use in 1995.
Society and culture
The lansoprazole molecule is off-patent and so generic drugs are available under many brand names in many countries; there are patents covering some formulations in effect as of 2015[update]. Patent protection expired on 10 November 2009.
Since 2009, lansoprazole has been available over the counter (OTC) in the U.S. as Prevacid 24HR and as Lansoprazole 24HR. In Australia, it is marketed by Pfizer as Zoton.
A one-month supply, in the United Kingdom, costs the NHS less than £5, as of 2019[update]. In the United States, the wholesale cost of this amount is about $5.40, as of 2019. In 2017, it was the 188th most commonly prescribed medication in the United States, with more than three million prescriptions.
In vitro experiments have shown that lansoprazole binds to the pathogenic form of tau protein. As of 2015[update] laboratory studies were underway on analogs of lansoprazole to explore their use as potential PET imaging agents for diagnosing tauopathies including Alzheimer's disease.
- ↑ 1.0 1.1 1.2 1.3 1.4 British national formulary : BNF 76 (76 ed.). Pharmaceutical Press. 2018. pp. 79–80. ISBN 9780857113382.
- ↑ 2.0 2.1 2.2 2.3 2.4 2.5 2.6 "Lansoprazole Monograph for Professionals". Drugs.com. American Society of Health-System Pharmacists. Archived from the original on 27 March 2019. Retrieved 3 March 2019.
- ↑ 3.0 3.1 3.2 3.3 3.4 3.5 "Lansoprazole capsule, delayed release pellets". DailyMed. 11 October 2016. Archived from the original on 24 July 2021. Retrieved 31 December 2019.
- ↑ 4.0 4.1 "WHOCC - ATC/DDD Index". www.whocc.no. Archived from the original on 26 September 2020. Retrieved 7 September 2020.
- ↑ 5.0 5.1 " Comparative effectiveness of proton pump inhibitors | Therapeutics Initiative". 28 June 2016. Archived from the original on 30 October 2020. Retrieved 14 July 2016.
- ↑ "Lansoprazole Use During Pregnancy". Drugs.com. Archived from the original on 20 June 2020. Retrieved 3 March 2019.
- ↑ Fischer, Jnos; Ganellin, C. Robin (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 445. ISBN 9783527607495. Archived from the original on 28 February 2019. Retrieved 28 February 2019.
- ↑ 8.0 8.1 "NADAC as of 2019-02-27". Centers for Medicare and Medicaid Services. Archived from the original on 6 March 2019. Retrieved 3 March 2019.
- ↑ 9.0 9.1 "The Top 300 of 2020". ClinCalc. Archived from the original on 12 February 2021. Retrieved 11 April 2020.
- ↑ 10.0 10.1 "Lansoprazole - Drug Usage Statistics". ClinCalc. Archived from the original on 28 August 2021. Retrieved 11 April 2020.
- ↑ Hirschowitz BI, Mohnen J, Shaw S (August 1996). "Long-term treatment with lansoprazole for patients with Zollinger-Ellison syndrome". Aliment. Pharmacol. Ther. 10 (4): 507–22. doi:10.1046/j.1365-2036.1996.10152000.x. PMID 8853754.
- ↑ British National Formulary Archived 21 February 2020 at the Wayback Machine (Free registration required) 1.3.5 Proton pump inhibitors
- ↑ British National Formulary Archived 21 February 2020 at the Wayback Machine (Free registration required) Lansoprazole
- ↑ "Prevacid (Lansoprazole) Drug Information: Side Effects and Drug Interactions - Prescribing Information at RxList". RxList. Archived from the original on 15 February 2016. Retrieved 9 February 2016.
- ↑ K C Singhal & S Z Rahman, Lansoprazole Induced Adverse Effects on the Skin, Indian Medical Gazette, July 2001, Vol. CXXXV. N0. 7: 223-225
- ↑ Sterry W, Assaf C (2007). "Erythroderma". In Bolognia JL (ed.). Dermatology. St. Louis: Mosby. p. 154. ISBN 978-1-4160-2999-1..
- ↑ British National Formulary Archived 28 August 2021 at the Wayback Machine (Free registration required) Lansoprazole interactions
- ↑ Piscitelli, S. C.; Goss, T. F.; Wilton, J. H.; d'Andrea, D. T.; Goldstein, H; Schentag, J. J. (1991). "Effects of ranitidine and sucralfate on ketoconazole bioavailability". Antimicrobial Agents and Chemotherapy. 35 (9): 1765–1771. doi:10.1128/aac.35.9.1765. PMC 245265. PMID 1952845.
- ↑ "Pharmacy Benefit Update". Archived from the original on 14 July 2014. Retrieved 2 July 2014.
- ↑ "Prevacid Pharmacology, Pharmacokinetics, Studies, Metabolism". RxList.com. 2007. Archived from the original on 16 August 2000. Retrieved 14 April 2007.
- ↑ Fischer, Janos; Ganellin, C. Robin (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 102. ISBN 9783527607495.
- ↑ Chorghade, Mukund S. (2006). Drug Discovery and Development, Volume 1: Drug Discovery. John Wiley & Sons. p. 201. ISBN 9780471780090.
- ↑ "Mosby's Drug Consult: Lansoprazole". Archived from the original on 8 February 2009. Retrieved 6 May 2008.
- ↑ drugs.com International availability of lansoprazole Archived 29 March 2016 at the Wayback Machine Page accessed 3 February 2015
- ↑ drugs.com Generic lansoprazole Archived 17 March 2017 at the Wayback Machine Page accessed 3 February 2015
- ↑ "Prevacid Drug Profile". Drugpatentwatch.com. Archived from the original on 1 March 2012. Retrieved 30 April 2020.
- ↑ "Teva to release Prevacid version when patent expires". Archived from the original on 6 February 2016. Retrieved 3 November 2009.
- ↑ "Prevacid 24 HR- lansoprazole capsule, delayed release". DailyMed. 7 August 2019. Archived from the original on 24 July 2021. Retrieved 31 December 2019.
- ↑ "Prevacid 24 HR- lansoprazole capsule, delayed release". DailyMed. 11 December 2019. Archived from the original on 24 July 2021. Retrieved 31 December 2019.
- ↑ "Lansoprazole 24 HR- lansoprazole capsule, delayed release". DailyMed. 21 December 2017. Archived from the original on 10 August 2020. Retrieved 31 December 2019.
- ↑ 31.0 31.1 Villemagne, VL; Fodero-Tavoletti, MT; Masters, CL; Rowe, CC (January 2015). "Tau imaging: early progress and future directions". The Lancet. Neurology. 14 (1): 114–24. doi:10.1016/s1474-4422(14)70252-2. PMID 25496902.
- Pages using duplicate arguments in template calls
- Webarchive template wayback links
- Use dmy dates from December 2019
- Articles with invalid date parameter in template
- Chem-molar-mass both hardcoded and calculated
- Chemical articles without CAS registry number
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without UNII source
- Drugs missing an ATC code
- Drugboxes which contain changes to watched fields
- Articles containing potentially dated statements from 2019
- All articles containing potentially dated statements
- Articles with hatnote templates targeting a nonexistent page
- Articles containing potentially dated statements from 2015
- All articles with unsourced statements
- Articles with unsourced statements from December 2019
- GlaxoSmithKline brands
- Novartis brands
- Phenol ethers
- Proton pump inhibitors
- AbbVie brands
- Takeda Pharmaceutical Company brands
- Trifluoromethyl compounds